<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04426968</url>
  </required_header>
  <id_info>
    <org_study_id>L47-HB-II-02</org_study_id>
    <nct_id>NCT04426968</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Hepalatide in Subjects With HBeAg-positive Chronic Hepatitis B</brief_title>
  <official_title>A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-effect Relationship Study of Hepalatide for Injection Combined With Pegylated Interferon in Subjects With HBeAg-positive Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai HEP Pharmaceatical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai HEP Pharmaceatical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-effect&#xD;
      Relationship Study of Hepalatide for Injection Combined with Pegylated Interferon in Subjects&#xD;
      with HBeAg-positive Chronic Hepatitis B&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a 4-arm parallel design, randomized, double-blind, placebo-controlled,&#xD;
      multicenter, dose-effect relationship, phase II clinical trial. The study is designed to&#xD;
      assess efficacy and safety of 3 Doses of hepalatide in Combination with Pegylated Interferon&#xD;
      Compared to Pegylated Interferon Alone in patients with Chronic Hepatitis B .Subjects will be&#xD;
      randomly assigned to the 2.1mg, 4.2mg, and 6.3mg dose groups , 32 subjects in each group .&#xD;
      The subjects in each dose group will be randomly and double-blindly administered the&#xD;
      corresponding dose of trial drug or placebo in a ratio of 3:1. The subjects in each dose&#xD;
      group who received placebo treatment combine as the placebo group. All subjects will receive&#xD;
      Pegylated Interferon treatment for 28 weeks as the basic treatment,trial drug or placebo&#xD;
      treatment for 24 weeks continuously , followed by a safety follow-up for 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 18, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>initial virological response</measure>
    <time_frame>24weeks</time_frame>
    <description>HBV DNA&lt;20 IU/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBV DNA down from baseline</measure>
    <time_frame>24weeks</time_frame>
    <description>HBV DNA down from baseline log10</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Virological suppression</measure>
    <time_frame>24weeks</time_frame>
    <description>HBV DNA &lt;2,000 IU/ml</description>
  </other_outcome>
  <other_outcome>
    <measure>No response</measure>
    <time_frame>24weeks</time_frame>
    <description>HBsAg &gt;20,000 IU/ml and HBV DNA lower than baseline &lt;2log10 IU/ml</description>
  </other_outcome>
  <other_outcome>
    <measure>Partial virological response</measure>
    <time_frame>24weeks</time_frame>
    <description>HBV DNA &gt;20 IU/ml and ≥2log10 IU/ml lower than baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>HBsAg is down from baseline</measure>
    <time_frame>24weeks</time_frame>
    <description>HBsAg is down from baseline log10</description>
  </other_outcome>
  <other_outcome>
    <measure>HBeAg turned negative</measure>
    <time_frame>24weeks</time_frame>
    <description>HBeAg &lt;0.05 index</description>
  </other_outcome>
  <other_outcome>
    <measure>HBeAg is down from baseline</measure>
    <time_frame>24weeks</time_frame>
    <description>HBeAg is down from baseline log10</description>
  </other_outcome>
  <other_outcome>
    <measure>ALT recurrence</measure>
    <time_frame>24weeks</time_frame>
    <description>ALT≤1.25×ULN</description>
  </other_outcome>
  <other_outcome>
    <measure>Histological response</measure>
    <time_frame>24weeks</time_frame>
    <description>Liver tissue inflammatory necrosis score reduced by ≥2 points with no increased liver fibrosis score; liver fibrosis score reduced by ≥1 point</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Hepalatide 2.1mg+Pegylated Interferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepalatide 4.2mg+Pegylated Interferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepalatide 6.3mg+Pegylated Interferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo+Pegylated Interferon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hepalatide 2.1mg</intervention_name>
    <description>2.1 mg/day subcutaneously (s.c.) for 24 week</description>
    <arm_group_label>Hepalatide 2.1mg+Pegylated Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hepalatide 4.2mg</intervention_name>
    <description>4.2mg/day subcutaneously (s.c.) for 24 week</description>
    <arm_group_label>Hepalatide 4.2mg+Pegylated Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hepalatide 6.3mg</intervention_name>
    <description>6.3mg/day subcutaneously (s.c.) for 24 week</description>
    <arm_group_label>Hepalatide 6.3mg+Pegylated Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo 2.1mg</intervention_name>
    <description>2.1 mg/day subcutaneously (s.c.) for 24 week</description>
    <arm_group_label>placebo+Pegylated Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo 4.2mg</intervention_name>
    <description>4.2 mg/day subcutaneously (s.c.) for 24 week</description>
    <arm_group_label>placebo+Pegylated Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo 6.3mg</intervention_name>
    <description>6.3 mg/day subcutaneously (s.c.) for 24 week</description>
    <arm_group_label>placebo+Pegylated Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon</intervention_name>
    <description>180 ug/week subcutaneously (s.c.) for 28 week</description>
    <arm_group_label>Hepalatide 2.1mg+Pegylated Interferon</arm_group_label>
    <arm_group_label>Hepalatide 4.2mg+Pegylated Interferon</arm_group_label>
    <arm_group_label>Hepalatide 6.3mg+Pegylated Interferon</arm_group_label>
    <arm_group_label>placebo+Pegylated Interferon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age from 18 to 60 years inclusively at the time of signing Informed Consent Form.&#xD;
&#xD;
          2. HBsAg or/and HBV DNA Positive for at least 6 months before Screening.&#xD;
&#xD;
          3. Subjects did not receive interferon treatment and did not receive&#xD;
             nucleotide/nucleoside analogue within 6 months&#xD;
&#xD;
          4. HBeAg positive&#xD;
&#xD;
          5. HBV DNA≥20,000 IU/ml&#xD;
&#xD;
          6. 2×ULN ≤ALT≤10×ULN&#xD;
&#xD;
          7. Serum total bilirubin&lt;2×ULN&#xD;
&#xD;
          8. Subjects had no history of decompensated liver disease（Ascites, jaundice, hepatic&#xD;
             encephalopathy, varicose hemorrhage）, serious heart disease (including unstable or&#xD;
             uncontrolled heart disease within 6 months),serious mental illness (especially&#xD;
             depression),organ transplantation .subjects have no uncontrolled epilepsy, mental&#xD;
             illness, diabetes and hypertension,no autoimmune disease, immune related extrahepatic&#xD;
             manifestations (vasculitis, purpura, nodular arteritis, peripheral neuropathy and&#xD;
             glomerulonephritis), thyroid disease, malignant tumor, immunosuppressive therapy; no&#xD;
             basic diseases and other serious diseases such as serious infection, retinal disease,&#xD;
             heart failure and chronic obstructive pulmonary disease; no alcohol and drug abuse.&#xD;
&#xD;
          9. Subjects must agree to use a highly effective contraception for 2 years , female&#xD;
             subjects are not pregnant or breastfeeding&#xD;
&#xD;
         10. Subjects did not donate blood or as clinical trial subjects within 3 months before&#xD;
             screening&#xD;
&#xD;
         11. Subjects have good compliance with the protocol&#xD;
&#xD;
         12. Subjects understood and agreed to sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Decompensated liver disease: direct bilirubin &gt; 1.2 × ULN, prothrombin time &gt; 1.2 ×&#xD;
             ULN, serum albumin &lt; 35 g / L&#xD;
&#xD;
          2. Hemocytopenia: neutrophil &lt; 1 × 10^9 / L, platelet &lt; 50 × 10^9 / L, hemoglobin &lt; 100g&#xD;
             / L (female) or hemoglobin &lt; 110g / L (male)&#xD;
&#xD;
          3. Severe liver fibrosis or cirrhosis: METAVIR score of liver biopsy is 4 points; or LSM&#xD;
             score of FibroScan ≥ 12.17 kPa&#xD;
&#xD;
          4. HAV,HCV,HDV,HEV or HIV infection&#xD;
&#xD;
          5. Allergic to interferon&#xD;
&#xD;
          6. Positive for anti-HBV Pre-S1 antibody.&#xD;
&#xD;
          7. Hamilton Depression Scale (HAMD, 17 items) score &gt; 17 points&#xD;
&#xD;
          8. Child-Pugh score&gt; 6 points&#xD;
&#xD;
          9. Female subjects pregnancy test positive&#xD;
&#xD;
         10. Other laboratories or auxiliary examinations are obviously abnormal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fusheng Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>The fifth medical center of PLA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The fifth medical center of PLA</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

